W D Schmitt
Corrigendum to "A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study": [Annals of Oncology (2019), volume 30:1279-1288]
Loibl S, Schmitt W, von Minckwitz G, Thomalla J, Kümmel S, Rautenberg B, Fasching P, Weber K, Rhiem K, Denkert C, Jackisch C, Rezai M, Engels K, Untch M, Burchardi N, Huober J, Sinn B, Blohmer J, Grischke E, Furlanetto J, Tesch H, Hanusch C, Schneeweiss A. Corrigendum to "A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study": [Annals of Oncology (2019), volume 30:1279-1288]. Ann Oncol 2022; 33:743-744.
May 18, 2022Corrigendum to "A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study": [Annals of Oncology (2019), volume 30:1279-1288]
May 18, 2022Ann Oncol 2022; 33:743-744
Loibl S, Schmitt W D, von Minckwitz G, Thomalla J, Kümmel S, Rautenberg B, Fasching P A, Weber K, Rhiem K, Denkert C, Jackisch C, Rezai M, Engels K, Untch M, Burchardi N, Huober Jens, Sinn B V, Blohmer J-U, Grischke E-M, Furlanetto J, Tesch H, Hanusch C, Schneeweiss A
Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study)
Fasching P, Rhiem K, Schneeweiss A, Engels K, Denkert C, Schmutzler R, Hahnen E, Untch M, Burchardi N, Blohmer J, Loibl S, Doering G, Uleer C, Schmitt W, Link T, Hauke J, Seither F, Jackisch C, Klare P, Schmatloch S, Hanusch C, Huober J, Stefek A, Seiler S, German Breast Group and Arbeitsgemeinschaft Gynäkologische Onkologie Breast. Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study). Ann Oncol 2020; 32:49-57.
Oct 21, 2020Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study)
Oct 21, 2020Ann Oncol 2020; 32:49-57
Fasching P A, Rhiem K, Schneeweiss A, Engels K, Denkert C, Schmutzler R K, Hahnen E, Untch M, Burchardi N, Blohmer J-U, Loibl S, Doering G, Uleer C, Schmitt W D, Link T, Hauke J, Seither F, Jackisch C, Klare P, Schmatloch S, Hanusch C, Huober Jens, Stefek A, Seiler S, German Breast Group and Arbeitsgemeinschaft Gynäkologische Onkologie Breast
Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo
Karn T, Schmitt W, Wu S, van Mackelenbergh M, Müller V, Schem C, Stickeler E, Fasching P, Jackisch C, Untch M, Schneeweiss A, Marmé F, Blohmer J, Denkert C, Weber K, Holtrich U, Hanusch C, Sinn B, Higgs B, Jank P, Sinn H, Huober J, Becker C, Loibl S. Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo. Ann Oncol 2020; 31:1216-1222.
May 24, 2020Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo
May 24, 2020Ann Oncol 2020; 31:1216-1222
Karn T, Schmitt W D, Wu S, van Mackelenbergh M, Müller V, Schem C, Stickeler E, Fasching P A, Jackisch C, Untch M, Schneeweiss A, Marmé F, Blohmer J-U, Denkert C, Weber K E, Holtrich U, Hanusch C, Sinn B V, Higgs B W, Jank P, Sinn H P, Huober Jens, Becker C, Loibl S
A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study
Loibl S, Schmitt W, von Minckwitz G, Thomalla J, Kümmel S, Rautenberg B, Fasching P, Weber K, Rhiem K, Denkert C, Jackisch C, Rezai M, Engels K, Untch M, Burchardi N, Huober J, Sinn B, Blohmer J, Grischke E, Furlanetto J, Tesch H, Hanusch C, Schneeweiss A. A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study. Ann Oncol 2019; 30:1279-1288.
Jan 1, 2019A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study
Jan 1, 2019Ann Oncol 2019; 30:1279-1288
Loibl S, Schmitt W D, von Minckwitz G, Thomalla J, Kümmel S, Rautenberg B, Fasching P A, Weber K, Rhiem K, Denkert C, Jackisch C, Rezai M, Engels K, Untch M, Burchardi N, Huober Jens, Sinn B V, Blohmer J-U, Grischke E-M, Furlanetto J, Tesch H, Hanusch C, Schneeweiss A
Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial
Denkert C, Barinoff J, Jackisch C, Prinzler J, Rüdiger T, Erbstösser E, Blohmer J, Budczies J, Mehta K, Fehm T, Huober J, Loibl S, Müller B, Eidtmann H, Schmitt W, Eiermann W, Gerber B, Tesch H, Hilfrich J, von Minckwitz G. Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial. Ann Oncol 2013; 24:2786-93.
Aug 22, 2013Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial
Aug 22, 2013Ann Oncol 2013; 24:2786-93
Denkert C, Barinoff J, Jackisch C, Prinzler J, Rüdiger T, Erbstösser E, Blohmer J U, Budczies J, Mehta K M, Fehm T, Huober Jens, Loibl S, Müller B M, Eidtmann H, Schmitt W D, Eiermann W, Gerber B, Tesch H, Hilfrich J, von Minckwitz G